Postoperative Ileus Management Therapeutics
1. Entereg patent expiration
Treatment: A method for binding a peripheral opioid receptor; A method of treating or preventing ileus; Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5250542 | CUBIST PHARMS | Peripherally selective piperidine carboxylate opioid antagonists |
Mar, 2016
(9 years ago) | |
| US6469030 | CUBIST PHARMS | Methods for the treatment and prevention of ileus |
Nov, 2020
(5 years ago) | |
| US8645160 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jun, 2029
(3 years from now) | |
| US8112290 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jul, 2030
(4 years from now) | |
| US8946262 | CUBIST PHARMS | Methods of preventing and treating gastrointestinal dysfunction |
Feb, 2030
(4 years from now) | |
| US5434171 | CUBIST PHARMS | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Dec, 2013
(12 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2013 |
| M(M-128) | Oct 18, 2016 |
Drugs and Companies using ALVIMOPAN ingredient
NCE-1 date: 20 May, 2012
Market Authorisation Date: 20 May, 2008
Dosage: CAPSULE
How can I launch a generic of ENTEREG before it's drug patent expiration?
More Information on Dosage
ENTEREG family patents
